[go: up one dir, main page]

MXPA02012750A - Compuestos farmaceuticos antagonistas del receptor de la vitronectina para su uso en terapia de combinacion. - Google Patents

Compuestos farmaceuticos antagonistas del receptor de la vitronectina para su uso en terapia de combinacion.

Info

Publication number
MXPA02012750A
MXPA02012750A MXPA02012750A MXPA02012750A MXPA02012750A MX PA02012750 A MXPA02012750 A MX PA02012750A MX PA02012750 A MXPA02012750 A MX PA02012750A MX PA02012750 A MXPA02012750 A MX PA02012750A MX PA02012750 A MXPA02012750 A MX PA02012750A
Authority
MX
Mexico
Prior art keywords
combination therapy
receptor antagonist
vitronectin receptor
pharmaceuticals
treatment
Prior art date
Application number
MXPA02012750A
Other languages
English (en)
Inventor
John A Barrett
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of MXPA02012750A publication Critical patent/MXPA02012750A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion describe kit(s) novedosos que comprenden compuestos de la formula (I): (Q)d-Ln-Ch o (Q)d-Ln-(Ch)d' util para el diagnostico y tratamiento del cancer en terapia de combinacion en un paciente. La presente invencion proporciona compuestos novedosos utiles para el tratamiento de la artritis reumatoide. Los ingredientes farmaceuticos comprenden una porcion objetivo que se enlaza al receptor que se sobreregula durante la angiogenesis, un grupo de enlace opcional, y un radioisotopo terapeuticamente efectivo o porcion formadora de imagen diagnosticamente efectiva.
MXPA02012750A 2000-06-21 2001-06-21 Compuestos farmaceuticos antagonistas del receptor de la vitronectina para su uso en terapia de combinacion. MXPA02012750A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21321000P 2000-06-21 2000-06-21
PCT/US2001/019793 WO2001097848A2 (en) 2000-06-21 2001-06-21 Vitronectin receptor antagonist pharmaceuticals

Publications (1)

Publication Number Publication Date
MXPA02012750A true MXPA02012750A (es) 2004-07-30

Family

ID=22794168

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012750A MXPA02012750A (es) 2000-06-21 2001-06-21 Compuestos farmaceuticos antagonistas del receptor de la vitronectina para su uso en terapia de combinacion.

Country Status (12)

Country Link
EP (1) EP1307226B1 (es)
JP (1) JP2004521066A (es)
CN (1) CN1582166A (es)
AT (1) ATE414541T1 (es)
AU (2) AU7296501A (es)
BR (1) BR0111880A (es)
CA (1) CA2412854C (es)
DE (1) DE60136632D1 (es)
IL (1) IL152941A0 (es)
MX (1) MXPA02012750A (es)
NZ (1) NZ522925A (es)
WO (1) WO2001097848A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2408323C (en) 2000-05-08 2012-06-12 The University Of British Columbia Drug delivery systems for photodynamic therapy
CA2412849A1 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
KR100978126B1 (ko) 2002-01-24 2010-08-26 반즈 쥬이쉬 하스피털 인테그린 표적화 조영제
EP1475105A1 (en) * 2003-05-09 2004-11-10 Schering AG Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
MXPA05012109A (es) * 2003-05-12 2006-02-08 Bristol Myers Squibb Pharma Co Compuestos antagonistas del receptor de vitronectina y su uso en la preparacion de radiofarmaceuticos.
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
WO2018096082A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
US11090395B2 (en) * 2018-09-14 2021-08-17 SeeCure Taiwan Co., Ltd. Composition for cross talk between estrogen receptors and cannabinoid receptors
AU2019382881B2 (en) 2018-11-23 2025-06-12 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE342262T1 (de) * 1996-11-27 2006-11-15 Bristol Myers Squibb Pharma Co Neue integrin rezeptor antagonisten
US6120995A (en) * 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
CA2349501A1 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Quinolone vitronectin receptor antagonist pharmaceuticals
EP1311302A2 (en) * 2000-06-21 2003-05-21 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
CA2412849A1 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
AU7002501A (en) * 2000-06-21 2002-01-02 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
US20020122768A1 (en) * 2000-07-06 2002-09-05 Shuang Liu Stable radiopharmaceutical compositions and methods for preparation thereof

Also Published As

Publication number Publication date
WO2001097848A2 (en) 2001-12-27
EP1307226B1 (en) 2008-11-19
IL152941A0 (en) 2003-06-24
CN1582166A (zh) 2005-02-16
NZ522925A (en) 2006-08-31
BR0111880A (pt) 2006-04-25
AU2001272965C1 (en) 2006-06-29
DE60136632D1 (de) 2009-01-02
WO2001097848A3 (en) 2003-03-13
JP2004521066A (ja) 2004-07-15
CA2412854C (en) 2010-08-17
ATE414541T1 (de) 2008-12-15
AU7296501A (en) 2002-01-02
EP1307226A2 (en) 2003-05-07
CA2412854A1 (en) 2001-12-27
AU2001272965B2 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
WO2001098294A3 (en) Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
WO2001097861A3 (en) Vitronectin receptor antagonist pharmaceuticals
WO2001097860A3 (en) Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
WO2000035492A3 (en) Vitronectin receptor antagonist pharmaceuticals
WO1999058162A3 (en) Pharmaceuticals for the imaging of angiogenic disorders
TR199901710T2 (xx) IL-8 resept�r antagonistleri.
IL173029A0 (en) Imaging agents
SE9902987D0 (sv) Novel compounds
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
DE60001983D1 (de) Bicyclische und tricyclische heteroaromatische verbindungen
AU7296501A (en) Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
NO20004795D0 (no) Peptidbaserte forbindelser
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
YU33203A (sh) Radioaktivna farmaceutska sredstva za dijagnostikovanje alchajmerove bolesti
ATE335515T1 (de) Morpholinobildgebung und therapie
WO2000035887A3 (en) Vitronectin receptor antagonist pharmaceuticals
ATE233754T1 (de) Diphenyl-piperidin derivate
TR200103680T2 (tr) IL-8 reseptör antagonistleri.
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
DK1140203T3 (da) Farmaceutiske præparater som vitronectinreceptorantagonist
TR199901761T2 (xx) IL-8 resept�r antagonistleri.
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
WO2000048581A3 (en) Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
DE69514100D1 (de) Substituierte kondensierte und verbrückte bicyclische verbindungen als therapeutische mittel
UA74421C2 (uk) Похідні індолону, які є антагоністами gal3 рецептора для лікування депресії і/або тривоги та композиції, придатні для такого лікування

Legal Events

Date Code Title Description
FA Abandonment or withdrawal